A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)

Anupamjeet Kaur Sekhon; Aniruddha Gollapalli; Dharamjeet Kaur; Bryan Janssen; Mark L. Stevens; Fernando Valerio; Miguel A. Sierra-Hoffman

doi:10.12659/AJCR.932961

26 November 2021 : Case report USA

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)

Unusual or unexpected effect of treatment

Anupamjeet Kaur Sekhon^1BDEF*, Aniruddha Gollapalli^1E, Dharamjeet Kaur^2E, Bryan Janssen^3D, Mark L. Stevens

^2E, Fernando Valerio^4AE, Miguel A. Sierra-Hoffman^2E

DOI: 10.12659/AJCR.932961

Am J Case Rep 2021; 22:e932961

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. Liver function test (LFT) values in a graph showing rapidly increasing LFTs in the acute phase of non-alcoholic steatohepatitis and decreasing after PCSK9 inhibitor treatment.

Back to the Article

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)

Your Privacy